UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

        Date of Report (date of earliest event reported): April 30, 2007


                               CEL-SCI CORPORATION
                         -----------------------------
             (Exact name of Registrant as specified in its charter)


     Colorado                           1-11889                  84-0916344
---------------------------       -------------------        ------------------
(State or other jurisdiction     (Commission File No.)         (IRS Employer
of incorporation)                                           Identification No.)

                              8229 Boone Blvd. #802
                                Vienna, VA 22182
               ---------------------------------------------------
          (Address of principal executive offices, including Zip Code)


Registrant's telephone number, including area code:    (703) 506-9460

                                       N/A
                            -----------------------
                (Former name or former address if changed since last report)


Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy  the filing  obligation  of the  registrant  under any of the  following
provisions (see General Instruction A.2. below)

[ ]  Written communications  pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17
     CFR 240.14a-12)

[ ]  Pre-commencement  communications  pursuant  to Rule  14d-2(b)  under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement  communications  pursuant to Rule  13e-14(c)  under the
     Exchange Act (17 CFR 240.13e-4(c))


<PAGE>

Item 3.01   Notice of Delisting or Failure to Satisfy a Continued  Listing Rule
            or Standard, Transfer of Listing

     In April 2007, CEL-SCI raised approximately  $15,000,000 from the sale to a
group of private  investors of  20,043,333  shares of common  stock,  10,021,667
Series L warrants,  and  10,021,667  Series M warrants.  The shares and warrants
were  sold as Units at a price of $0.75 per Unit.  Each  Unit  consisted  of one
share of CEL-SCI's common stock,  one-half of a Series L warrant and one-half of
a Series M warrant.

     Each Series L warrant  allows the holder to purchase one share of CEL-SCI's
common stock for $0.75.  Each Series M warrant allows the holder to purchase one
share of CEL-SCI's common stock for $2.00. The Series L and M warrants expire on
March 31, 2012.

     On April 30, 2007 CEL-SCI received a Warning Letter from the American Stock
Exchange  advising  CEL-SCI  that it had  failed to file an  Additional  Listing
Application with the AMEX for the sale of the shares in the April financing.

     Section 301 of the AMEX Company Guide provides that a listed company is not
permitted to issue additional securities of a listed class until it has filed an
application  for  the  listing  of  such  additional   securities  and  received
notification from the AMEX that the securities have been approved for listing.

     On May 4, 2007 the AMEX notified  CEL-SCI that the shares sold in the April
financing had been approved for listing.

     The  Warning  Letter  did not  affect  CEL-SCI's  listing  on the  AMEX and
CEL-SCI's common stock continues to trade under the symbol "CVM".

Item 9.01   Financial Statements and Exhibits


           None


                                       2
<PAGE>

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Date:  May 4, 2007.
                                    CEL-SCI CORPORATION



                                 By:  /s/ Geert R. Kersten
                                      -------------------------------------
                                      Geert R. Kersten, Chief Executive Officer
[{"type": "8-K", "sequence": "1", "filename": "april8k507.txt", "description": "APRIL 8-K", "secsgml_size_bytes": 4349}]
{"company-data": {"conformed-name": "CEL SCI CORP", "cik": "0000725363", "assigned-sic": "2836", "irs-number": "840916344", "state-of-incorporation": "CO", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-11889", "film-number": "07821529"}, "business-address": {"street1": "8229 BOONE BLVD .", "street2": "SUITE 802", "city": "VIENNA", "state": "VA", "zip": "22182", "phone": "7035069460"}, "mail-address": {"street1": "8229 BOONE BLVD.", "street2": "SUITE 802", "city": "VIENNA", "state": "VA", "zip": "22182"}, "former-company": {"former-conformed-name": "INTERLEUKIN 2 INC", "date-changed": "19880317"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

        Date of Report (date of earliest event reported): April 30, 2007

                               CEL-SCI CORPORATION
                         -----------------------------
             (Exact name of Registrant as specified in its charter)

     Colorado                           1-11889                  84-0916344
---------------------------       -------------------        ------------------
(State or other jurisdiction     (Commission File No.)         (IRS Employer
of incorporation)                                           Identification No.)

                              8229 Boone Blvd. #802
                                Vienna, VA 22182
               ---------------------------------------------------
          (Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code:    (703) 506-9460

                                       N/A
                            -----------------------
                (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy  the filing  obligation  of the  registrant  under any of the  following
provisions (see General Instruction A.2. below)

[ ]  Written communications  pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17
     CFR 240.14a-12)

[ ]  Pre-commencement  communications  pursuant  to Rule  14d-2(b)  under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement  communications  pursuant to Rule  13e-14(c)  under the
     Exchange Act (17 CFR 240.13e-4(c))
Item 3.01   Notice of Delisting or Failure to Satisfy a Continued  Listing Rule
            or Standard, Transfer of Listing

     In April 2007, CEL-SCI raised approximately  $15,000,000 from the sale to a
group of private  investors of  20,043,333  shares of common  stock,  10,021,667
Series L warrants,  and  10,021,667  Series M warrants.  The shares and warrants
were  sold as Units at a price of $0.75 per Unit.  Each  Unit  consisted  of one
share of CEL-SCI's common stock,  one-half of a Series L warrant and one-half of
a Series M warrant.

     Each Series L warrant  allows the holder to purchase one share of CEL-SCI's
common stock for $0.75.  Each Series M warrant allows the holder to purchase one
share of CEL-SCI's common stock for $2.00. The Series L and M warrants expire on
March 31, 2012.

     On April 30, 2007 CEL-SCI received a Warning Letter from the American Stock
Exchange  advising  CEL-SCI  that it had  failed to file an  Additional  Listing
Application with the AMEX for the sale of the shares in the April financing.

     Section 301 of the AMEX Company Guide provides that a listed company is not
permitted to issue additional securities of a listed class until it has filed an
application  for  the  listing  of  such  additional   securities  and  received
notification from the AMEX that the securities have been approved for listing.

     On May 4, 2007 the AMEX notified  CEL-SCI that the shares sold in the April
financing had been approved for listing.

     The  Warning  Letter  did not  affect  CEL-SCI's  listing  on the  AMEX and
CEL-SCI's common stock continues to trade under the symbol "CVM".

Item 9.01   Financial Statements and Exhibits

           None

                                       2
SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:  May 4, 2007.
                                    CEL-SCI CORPORATION

                                 By:  /s/ Geert R. Kersten
                                      -------------------------------------
                                      Geert R. Kersten, Chief Executive Officer